We are Prime

Home
United Kingdom
Knutsford
We are Prime

Prime We provide the world’s leading biotech, pharma and healthcare businesses with professional communications and strategic consultancy services.

Prime Global
The Medical Communications People

Prime Global is a group of seven full-service medical communications agencies and four specialist consultancies. Through our offices across the UK and US, our exceptionally highly qualified scientific teams deliver expertise across a wide range of therapy areas, with a passionate belief in the value of creative, innovative science communication. People are at the heart of everything we do. From the colleagues we work with to the clients we support every day, and ultimately to patients everywhere whose lives we help to make better. www.primeglobalpeople.com

18/11/2025

It’s nearly time! ✨

Tomorrow night, the Awards celebrate excellence, innovation, and impact across the healthcare and life sciences industry, and we’re honoured to be finalists for not one, but two categories:

🎉 Award for Patient-Centricity
🎉 Excellence in Innovation

We’ve been shortlisted for our work supporting young people with chronic rheumatological conditions and their families, and for creating ‘Rheumbot’ - a life-changing interactive app with Great Ormond Street Hospital and Charity offering advice from HCPs, hints and tips from parents, and guided coaching conversations.

With an average user score of 4.3 out of 5 and an NPS of 70, the results speak for themselves.

But the real impact is best captured in the words of the patients and their families: “It made me feel safe, more confident, less lonely, less of a burden to the nurse, and [it] had infinite patience”. “[It] empowers you, as a parent, to ask the tricky questions.”

Find out more about the project here: https://loom.ly/5gfNEoE

Fingers crossed for tomorrow evening! 🙌

17/11/2025

According to a 2024 report from the World Health Organization (WHO), antimicrobial resistance (AMR) is the third leading cause of mortality worldwide, 🦠

projecting that AMR will cause 39 million deaths globally over the next 25 years. That is, more than three deaths every minute.

Tomorrow marks the start of World Antimicrobial Awareness Week (18–24 November). This year’s theme, “Act Now: Protect Our Present, Secure Our Future”, calls for urgent, collective action across science, healthcare, and society.

We need innovation to develop new treatments, collaboration through the One Health approach, and stewardship to use existing medicines responsibly.

Protecting the medicines that protect us is everyone’s responsibility.

17/11/2025

Don’t miss Wednesday’s ISMPP International Society for Medical Publication Professionals webinar featuring our very own Mel Purves!

Mel will join panelists Sian Kneller, Director, Global Content Design & Delivery, Oncology at GSK, Melissa Goodman, Director, Annual Meeting Programs, Convention & Meetings at American Urological Association and Kindiya Geghman, Vice President, Medical & Scientific Services at Ashfield MedComms, to explore the various types of scientific congresses and their affiliations.

What to expect:
📄 An overview of congresses and their role within the publications ecosystem
✍️ Key components of congress publication activities
🌎 Real-world insights from experts across pharma, agency, and congress organizations

Register here: https://loom.ly/_JyOnIs

14/11/2025

Two congresses, one mission: creating optimal portfolio value 🚀

From MedAffairs Transformation to ISPOR, Medical Affairs and HEOR/Market Access teams can work collaboratively, guided by the VISTA framework, to climb the optimal path of value creation and patient impact.

Following the recent conference, we caught up with Rebecca Massey, Idaira Rodríguez & the team to hear their key takeaways:

💙 Patient centricity was at the heart of discussions
Sessions focused on integrating patient perspectives across value assessment, pricing, reimbursement, and market access, accelerating truly patient-centered decision making.

🏥 Joint clinical assessments (JCAs) present challenges and uncertainties
Pre-empting market access and JCA challenges earlier in R&D, as well as optimising cross-functional working, will be pivotal for successful outcomes and improved patient access.

🤖 AI can enhance efficiency, but ethical considerations remain
The consensus was clear: technology can support the process, but the human element remains essential.

Many thanks again to all who attended Sue’s VISTA session at MedAffairs Transformation and visited our stand at ISPOR, and thank you for having us, Evidence Life Sciences and ISPOR—The Professional Society for Health Economics and Outcomes Research!

13/11/2025

We’re delighted to announce that Megan Pollack has joined our leadership team as Vice President at Prime Aventine – our US market access team.

Based in the US, Megan brings extensive experience in payer access and value communications. She previously led US medical and value communications for 9 years, delivering AMCP dossiers, pre-approval information exchange, and CMS Inflation Reduction Act response documents.

Megan also has direct experience in clinical pharmacy and laboratory bench research which gives her unique insight into the full drug development process, from product development to post-approval market access and clinical use.

This appointment marks a significant step in Prime’s continued growth and commitment to expanding our market access services in the US, and Megan's understanding of the landscape will be invaluable to us.

Welcome to Prime’s leadership team, Megan! 👏

Learn more: https://loom.ly/YTel5ZQ

12/11/2025

Heading to the ISMPP International Society for Medical Publication Professionals Academy in Boston tomorrow? Valerie Moss will see you there!

Val will be co-hosting two sessions alongside Jennifer Ghith, Senior Director, Channel Integration and Analytics Lead, Global Scientific Communications at GSK, and Monica Mody, Vice President, Scientific Communications at Madrigal Pharmaceuticals.

Together, they’ll explore two of the most talked-about topics in the community:

🧩 Lean Teams, Smart Working: AI Implementation for Small Companies and/or Small Teams with Big Ideas
🤖 Will AI Replace the Scientific Communications Professional or Make You Irreplaceable? New Skillsets in the AI Age

Expect fresh perspectives, practical insights, and an honest look at how AI is transforming the future of medical and scientific communications.

10/11/2025

This year’s ESMO - European Society for Medical Oncology Congress was brimming with optimism for the future of oncology, and we’re still feeling inspired!

Reflecting on her time at the meeting, Valerie Moss shares her top three takeaways:

1️⃣ Precision oncology is accelerating
Circulating tumor DNA (ctDNA) was a prominent theme at , evolving from a research tool to a driver of personalized cancer care. The pivotal IMvigor011 trial showcased how ctDNA can guide earlier intervention in muscle-invasive bladder cancer before recurrence appears on imaging, with the potential to save patients at lower risk from unnecessary treatment.

2️⃣ ADCs and combination strategies are rewriting the playbook
Antibody-drug conjugates (ADCs) took center stage across many tumor types. One HER2-targeted ADC combined with a PD-1 inhibitor nearly doubled overall survival versus standard of care chemotherapy in unresectable locally advanced/metastatic urothelial cancer, earning spontaneous applause from the audience at a packed presidential session and signaling powerful new treatment possibilities.

3️⃣ From breakthroughs to real change
Presidential sessions delivered other practice-changing data across HER2+ breast, muscle-invasive bladder, and platinum-resistant ovarian cancers. The message was clear: earlier treatment, smarter targeting, and better biomarkers are converging to transform patient outcomes.

The future of oncology is taking shape, and collaboration will be key to accelerating it. We’re ready to play our part.

Swipe to learn more 👉

10/11/2025

On World Diabetes Day, we’re championing better workplace support for people living with diabetes.

Did you know?

📊 7 in 10 people with diabetes are of working age
📊 3 in 4 have experienced anxiety, depression, or another mental health condition because of their diabetes
📊 4 in 5 have experienced diabetes burnout, emotional fatigue and a sense of being overwhelmed

This year’s theme, “Diabetes and the Workplace,” reminds us that small changes in awareness, policy, and understanding can make a real difference to daily wellbeing and long-term health.

Let’s work together to create supportive, inclusive workplaces. 💙

Share your experiences, tips, or ideas for making workplaces diabetes-friendly in the comments and let’s learn from each other.

07/11/2025

Did you miss Sue O’Leary’s session at the MedAffairs Transformation conference?

In her talk, Sue shared how the VISTA (Value and Impact Strategic Trends Assessment) framework enables teams to embed value thinking across functions and deliver better outcomes for patients, payers, and pharma alike.

Our latest whitepaper, “Why Value Demonstration Is Everyone’s Business”, explores this further through the idea of the “value red thread” – a mindset that connects R&D, Medical, HEOR, Market Access and Commercial from asset selection to post launch.

It invites teams to consider:
💡 Are we defining value early enough?
💡 Are our trial endpoints meaningful to both patients and payers?
💡 Are our data and communications aligned to sustain access post launch?

Because demonstrating value isn’t the responsibility of one function alone: it’s everyone’s business.

Download the whitepaper here: https://loom.ly/w_tvouI

05/11/2025

Innovation meets collaboration at ISPOR—The Professional Society for Health Economics and Outcomes Research Europe in Glasgow this weekend, and Rebecca Massey, Jonathan Evans, Idaira Rodriguez Santana, and Lorraine Munetsi from our Evidence and Access team will be there to join the conversation! 💬

Bringing together experts in HEOR, real-world evidence, and market access, our team partners with clients across the lifecycle to generate robust clinical evidence, demonstrate value, and support timely patient access to new treatments.

Reflecting this year’s theme, we integrate science, storytelling, and access to shape strategies that ensure every innovation delivers real impact for patients and healthcare systems. 🔎

We’re looking forward to connecting with peers who share our passion for evidence and access. 💙

If you’re attending, come say hello at stand 310!

03/11/2025

This week, we’re shining the spotlight on Sue O’Leary, Executive Vice President of our Evidence and Access team at Prime.

Sue began her career as a UK hospital pharmacist, managing formularies and understanding first-hand the need to optimize limited healthcare resources. That grounding in real-world healthcare continues to shape her approach today. 🧑‍⚕️

During her 15 years at AstraZeneca, Sue helped shape new organizational initiatives, as health technology assessments were an emerging concept, and “global-to-local” activities became key to successful brand launches.

Now leading our Evidence and Access team across the US and Europe, Sue partners with clients throughout the lifecycle to ensure that value demonstration and evidence generation deliver impact – not just at launch, but long after.

As a passionate advocate for cross-functional collaboration, she believes that successful market access depends on integrating strategic thinking early and breaking down silos, from emerging brand development through to launch. 🎯

Heading to Evidence Life Science’s MedAffairs Transformation later this week? Don’t miss Sue’s session on demonstrating value through the VISTA (Value and Impact Strategic Trends Assessment) framework – she’d love to connect with you there!

31/10/2025

Thank you World Orphan Drug Congress Europe for an inspiring few days!

We loved connecting with scientists, biotechs, pharma leaders, regulators, investors, and patient advocates to explore the latest advances in orphan drug innovation.

For Jonathan Evans, three key takeaways stood out:

🔬 Patients as partners: Rare disease patients are increasingly shaping every stage of drug development, from defining unmet need and designing clinical trials to involvement in the regulatory process.

🔍 Embracing emerging tech: Understanding AI, biotechnologies, and the associated regulatory adjustments required in rare disease is essential to improving diagnosis, measuring outcomes, and enhancing patient care.

💙 Patient passion: The energy of patients and advocates throughout the congress was truly inspiring.

Huge thanks to our partners at the European Haemophilia Consortium for collaborating with us on our research poster!

Address

Knutsford

Telephone

+441565752100

Website

http://www.primeglobalpeople.com/

Alerts

Be the first to know and let us send you an email when We are Prime posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Mindful Walks
Northwich

Want your practice to be the top-listed Clinic in Knutsford?

18/11/2025

17/11/2025

17/11/2025

14/11/2025

13/11/2025

12/11/2025

10/11/2025

10/11/2025

07/11/2025

05/11/2025

03/11/2025

31/10/2025

Address

Telephone

Website

Alerts

Shortcuts

Featured

Share

Category